Few recent listings show the gap between an IPO price and a first trade as clearly as Cerebras. The AI chipmaker priced at $185 a share on May 13, 2026. The first trade the next day was at $350. By the close on October 30, the stock stood at $109.18, roughly 41% below the offer and about 72% below its all-time high of $386.34.
Those are dated figures, not a live quote, and they will go stale quickly. They show why it matters what instrument you hold in a stock’s first months.
From withdrawn filing to Nasdaq
Cerebras’s route to the market wasn’t direct. It filed publicly for an IPO in September 2024, then withdrew the plan about a year later and kept raising private capital. A $1.1 billion Series G in September 2025 valued it at $8.1 billion, and a $1 billion Series H in February 2026 valued it at about $23 billion.
When it returned, the terms rose quickly:
- Ticker and venue: CBRS, Nasdaq, with trading from May 14, 2026
- Marketing range: first $115 to $125, later raised to $150 to $160
- Offer price: $185
- Shares sold: 30 million Class A
- Proceeds: $5.55 billion
- First day: open $350, close $311.07, up about 68%
- Lead book-runners: Morgan Stanley, Citigroup, Barclays, UBS, Mizuho and TD Securities
Valuation depends on the share count used. IPOScoop gives about $39.8 billion at pricing, while the fully diluted figure reported by Reuters was about $56.4 billion. Estimates for the first-day close range from about $86 billion to about $95 billion. Canborsa lists $43.8 billion dated September 2026, and StockAnalysis data cited by one report gives about $25.9 billion for October 22. Always check the date and the basis before comparing two market caps.
What the prospectus and results say
Public buyers get Class A stock, with one vote per share. Class B stock has 20 votes, so early holders keep outsized influence.
The business has grown quickly. Revenue was $510 million in 2025, up 76%, and Cerebras reported net income of $237.8 million that year. Reported 2026 quarters look more complicated. The Q2 report showed a GAAP net loss of $450.5 million, core gross margin of 40.6% and remaining performance obligations of $25.4 billion, according to Zacks.
Three issues stand out for anyone studying the stock:
- Customer concentration. MBZUAI and G42 made up about 86% of 2025 revenue, according to a Techi review of the filing. In Q2 2026, three customers accounted for 34%, 32% and 10% of revenue.
- Reliance on OpenAI. A multi-year deal worth more than $20 billion, covering 750 megawatts of compute, makes up much of the backlog. OpenAI also holds a warrant over about 33.4 million shares, subject to vesting.
- Share supply. The lock-up was staggered. Reports say the final release falls on November 9, 2026, with third-quarter results due on November 12. Company insiders have already sold under earlier windows.
The perp on Canborsa
Canborsa’s page on Cerebras Systems stock and IPO shows a live perpetual contract, CBRS-PERP. Its market page describes the contract as tracking the Nasdaq stock, though neither page names the reference price source. The main terms shown are:
- Leverage: up to 10x, half the level shown for SpaceX on the same venue
- Margin and settlement: USDC
- Fees: 0.055% per side, 0.11% round trip
- Funding: charged every hour
- Minimum: from $1
- Sign-up: email, X or a wallet
The contract conveys no Cerebras shares. There’s no vote, no share in company value beyond the price change, and no conversion into stock.
Illustrative example, not a forecast. A trader posts $500 of margin at 4x, for $2,000 of notional. Fees are $1.10 to open and $1.10 to close. A 15% move in either direction changes the position by $300, before funding and fees. A 25% adverse move would equal the entire margin, and liquidation would come earlier in practice. At 10x, a 10% adverse move would do the same. For a stock that has fallen more than 15% around an earnings report before, those aren’t remote distances.
Other ways to hold CBRS
Now that Cerebras is listed, buying Class A shares through a broker offering Nasdaq stocks is the direct route to ownership. Canborsa’s page also lists listed funds, secondary marketplaces and employee-share vehicles. Those are private-market routes that were more relevant before the IPO. With shares on Nasdaq, they involve extra steps, and a buyer should ask what they add. They may also bring eligibility tests, sponsor fees and transfer limits. A listed fund may not hold Cerebras at all.
Tokenized products are another category. Kraken’s CBRSx is described as backed one-to-one by Class A shares held with a third-party custodian, and it trades when Nasdaq is closed. It offers price exposure, without voting rights, and adds issuer and custodian risk. Availability depends on the issuer’s own rules.
Who can use each one
Shares are generally open to anyone whose broker offers Nasdaq stocks, subject to local rules. Perp access is more limited. Canborsa’s terms state the interface isn’t available to people or entities that are resident, located or incorporated in the United States, or to those in sanctioned jurisdictions, including citizens of those places wherever they live. Using a VPN to get around this is prohibited.
In the EU, ESMA’s February 2026 statement says perpetual contracts meeting the CFD definition are likely covered by national CFD measures, regardless of the name. UK retail consumers can’t be sold crypto-asset derivatives by firms acting in or from the UK, under a ban in force since January 2021, so it’s worth checking how a stablecoin-settled stock contract is treated. Terms for tokenized stocks vary by issuer and country as well. Elsewhere, take local advice.
Before you act
Treat any quoted number here as history. For the live picture, look at the Nasdaq quote, the latest quarterly filing and the lock-up language in the prospectus.
This article is for educational purposes only and is not financial advice. Leveraged derivatives and private-market investments carry a high risk of loss.
